ИИ ежедневно анализирует ведущие российские и международные источники, отбирает значимые исследования, рекомендации и новости и представляет их врачу в кратком структурированном формате.
Конференции, вебинары и симпозиумы по онкологии от ведущих организаций мира.
Организатор: ESTRO
Организатор: ESTRO
Организатор: MASCC Supportive Care Events
Организатор: ESTRO
Организатор: Российское общество онкоурологов
Организатор: ESMO Meeting Calendar
Вебинар по опухолям центральной нервной системы: глиобластома, метастазы в ЦНС, менингиомы.
Организатор: RUSSCO
Организатор: НМИЦ радиологии Минздрава России
Организатор: НМИЦ радиологии Минздрава России
Организатор: EBMT Educational Events & Meetings
Downloadable pocket guide to assist oncology nurses in quickly identifying and assessing the severity of ADC-related adverse events associated with sacituzumab govitecan and datopotamab deruxtecan in the management of patients with HR-positive, HER2-negative metastatic breast cancer, including the evolving nursing role, factors that nurses should consider to deliver safe and high-quality care, measures to use to optimize the early recognition of adverse events, and institute early intervention to improve adherence while utilizing shared treatment decision-making approaches to optimize treatment outcomes.
Организатор: Decera Clinical
In this podcast, experts review practice-informing data presented at the ASCO 2026 annual conference that may reshape treatment decisions in metastatic breast cancer. The discussion examines ctDNA-guided treatment adaptation for emergent ESR1 mutations in HR-positive/HER2-negative disease, emerging endocrine-based precision strategies targeting ER and PI3K/AKT signaling, and first-line TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer. The experts place the SERENA-6, ELEVATE, PIKALO-1, ASCENT-04, ASCENT-03, and TROPION-Breast02 findings in clinical context and how the results, including biomarker testing, immunotherapy eligibility, sequencing, safety, and the maturity of the evidence are influencing their clinical practice.
Организатор: Decera Clinical
Организатор: College of American Pathologists (CAP) Events
Esaminare le evidenze fondamentali degli studi di fase III a sostegno dei recenti aggiornamenti delle indicazioni approvate per gli anticorpi farmaco-coniugati (ADC) anti-TROP2 nel carcinoma mammario metastatico HR-positivo/HER2-negativo e triplo-negativo, con particolare attenzione al ruolo dei nuovi dati di efficacia e sicurezza nella scelta del trattamento. Approfondire i criteri adottati dagli esperti per la scelta della terapia in prima linea e nelle linee successive, tenendo conto della possibilità di offire un trattamento contenete immunoterapia e del profilo degli eventi avversi degli ADC diretti contro TROP2 disponibili. Infine, approfondire come monitorare i potenziali eventi avversi che possono limitare la prosecuzione della terapia e come prevenirli e trattarli, integrando allo stesso tempo della terapia, terapiae di supporto finalizzate al miglioramento della qualità di vita.
Организатор: Decera Clinical
Организатор: College of American Pathologists (CAP) Events
Организатор: College of American Pathologists (CAP) Events
Организатор: College of American Pathologists (CAP) Events
Организатор: Ассоциация специалистов по проблемам меланомы
Организатор: ESTRO
Организатор: MASCC Supportive Care Events
Erkunden Sie wegweisende Phase-III-Evidenz, die zu den kürzlichen aktualisierten Arzneimittel-Zulassungserweiterung für TROP2-ADCs bei metastasiertem HR-positivem/HER2-negativem und dreifach negativem Mammakarzinom geführt hat. Ein Schwerpunkt sind die neuen Wirksamkeits- und Sicherheitsdaten, die Behandlungsauswahl beeinflussen. Erfahren Sie mehr über die Abwägungen von Expertinnen und Experten bei der Auswahl einer Therapie in der Erstlinien- und Folgelinienbehandlung, basierend auf der Eignung für eine Immuntherapie und dem Nebenwirkungsprofil der verfügbaren TROP2-gerichteten Antikörper-Wirkstoff-Konjugate (ADCs). Lernen Sie schließlich, wie Sie potenzielle unerwünschte Ereignisse, die die Therapiedauer beeinträchtigen könnten, antizipieren und wie Sie diese mit Supportivtherapien abmildern können.
Организатор: Decera Clinical
Организатор: EAU
Организатор: Decera Clinical
In this commentary, experts review the evolving role of TROP-2–directed antibody–drug conjugates (ADCs) in metastatic triple-negative breast cancer, with emphasis on first-line treatment selection, sequencing after progression, and management of agent-specific toxicities. The discussion examines phase III data from KEYNOTE-355, ASCENT-04/KEYNOTE-D19, ASCENT-03, TROPION-Breast02, and ASCENT, including progression-free survival, overall survival, response rates, and PFS2, while highlighting important differences in trial design that limit cross-trial comparisons. The experts also address how PD-L1 and germline BRCA1/2 status, prior therapy, disease characteristics, toxicity profiles, supportive care needs, and treatment schedules inform ADC selection and sequencing. Practical considerations related to managing neutropenia, diarrhea, stomatitis, ocular toxicity, and ILD/pneumonitis are reviewed alongside strategies to support timely treatment, toxicity monitoring, biomarker testing, and equitable access to ADC therapy and clinical trials.
Организатор: Decera Clinical
Организатор: EORTC
Организатор: Decera Clinical
Despite the evolving evidence supporting earlier use of BCMA-directed CAR T-cell therapy in multiple myeloma, practical gaps remain in patient selection, referral timing, bridging therapy, treatment sequencing, and shared-care coordination. This interactive case challenge follows an older, fit patient with high-risk multiple myeloma who experiences an early relapse and is being considered for BCMA-directed CAR T-cell therapy. Through expert-guided branching decisions, you will evaluate CAR T-cell eligibility, select an appropriate bridging strategy, consider sequencing with bispecific antibodies and other therapies, and recognize and manage delayed CAR T-cell therapy–associated neurotoxicity.
Организатор: Decera Clinical
Эксперты в области онкологии, радиологии и ядерной медицины — о внедрении высокотехнологичной помощи в стандарты лечения. Клиника Медскан | Hadassah, Сколково.
Организатор: Клиника Hadassah при поддержке Фонда ММК и GE HealthCare
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: ESMO Meeting Calendar
Организатор: EAU
Get practical guidance on a wide range of hematologic malignancies at this exciting satellite symposia held both in-person in New Orleans and virtually.
Организатор: Decera Clinical
Get access to presentation slidesets, on-demand webcasts, and expert commentaries on oncology & hematology topics.
Организатор: Decera Clinical
With Decera Clinical Education (formerly CCO) access the latest oncology CME/CE activities and live events on breast, lung, hematologic, and other cancer types. Get evidence-based education for the entire oncology care team.
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
This toolkit empowers patients with multiple myeloma and their care partners to participate in shared decision-making throughout the disease course by understanding treatment options and sequencing, monitoring response, recognizing and reporting side effects, and accessing supportive care, financial assistance, and clinical trials. Download now to review important information about treatment for multiple myeloma, including key questions to ask your care team.
Организатор: Decera Clinical
New approvals in the neoadjuvant and adjuvant settings of HER2-positive early breast cancer are increasing the complexity of selecting optimal treatment. This patient case challenges you to navigate the treatment options based on initial disease burden, treatment tolerability, HER2 reassessment, response to neoadjuvant treatment, and currently available trial evidence.
Организатор: Decera Clinical
Discover how to recognize, monitor, and escalate delayed and long-term toxicities after CAR T-cell therapy in this oncology nursing pocket guide designed to turn current guidelines and expert recommendations into concise clinical workflows to support risk assessment, patient and caregiver education, symptom triage, and timely communication with the cellular therapy center. Topics covered include cytopenias, infections, hypogammaglobulinemia, vaccination counseling, antimicrobial prophylaxis, and more.
Организатор: Decera Clinical
Downloadable slides on the evolving management of immune thrombocytopenia (ITP), including disease pathophysiology, treatment-related burden, and current guideline-based approaches across lines of therapy. The slides review evidence for established options such as corticosteroids, rituximab, thrombopoietin receptor agonists (TPO-RAs), fostamatinib, and splenectomy, as well as clinical trial data for newer and emerging immune-targeted therapies, including rilzabrutinib, ianalumab, efgartigimod, and mezagitamab. Key studies reviewed include LUNA 3, VAYHIT1/2/3, and ADVANCE IV, with attention to platelet response, treatment failure, fatigue, bleeding, safety, and sustained response off treatment. The slides also emphasize durability-focused treatment goals, TPO-RA tapering, and shared decision-making to help individualize therapy according to disease control, treatment burden, adverse effects, and patient preferences.
Организатор: Decera Clinical
As oral targeted therapies for HR-positive/HER2-negative breast cancer expand, nurses need practical guidance to identify and manage overlapping adverse events, support treatment adherence, and help patients achieve the full benefit of therapy. These downloadable slides summarize indications, dosing, and administration of approved oral targeted agents along with nursing-focused clinical pearls related to AE monitoring and management.
Организатор: Decera Clinical
This expert commentary examines the evolving role of GPRC5D-directed therapy in multiple myeloma, including the biologic rationale for targeting GPRC5D and clinical evidence supporting talquetamab across treatment settings. It also explores emerging approaches to sequencing and combining GPRC5D- and BCMA-directed therapies, ongoing studies evaluating earlier-line use such as the phase III MonumenTAL-3 trial, and practical strategies for recognizing and managing unique toxicities associated with GPRC5D-targeted treatment like skin, nail, and taste changes.
Организатор: Decera Clinical
In relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of alternative targets. Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates, bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.
Организатор: Decera Clinical
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: НМИЦ радиологии Минздрава России
Ежегодное заседание Американского общества радиационной онкологии. Лучевая терапия и радиационная онкология.
Организатор: ASTRO
Организатор: ESTRO
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: ESGO Meeting Calendar
Организатор: EAU
Организатор: EAU
Организатор: Onco-Academy
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Вебинар по лечению метастатического рака молочной железы: новые данные и клинические решения.
Организатор: RUSSCO
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: ASTCT Meetings
Организатор: EAU
Организатор: Onco-Academy
Организатор: SIOP Community Calendar
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: Onco-Academy
Организатор: Onco-Academy
Организатор: MASCC Supportive Care Events
Организатор: AACR Meetings & Workshops
Вебинар по иммунотерапии меланомы кожи: ингибиторы контрольных точек, комбинированные режимы.
Организатор: RUSSCO
Организатор: EBMT Educational Events & Meetings
Организатор: College of American Pathologists (CAP) Events
Организатор: SIOP Community Calendar
Организатор: College of American Pathologists (CAP) Events
Организатор: College of American Pathologists (CAP) Events
Организатор: ESMO Meeting Calendar
Межрегиональная междисциплинарная научно-практическая онкологическая конференция: гериатрическая онкология, кардиоонкология, коморбидный пациент, ИИ в онкологии. Экзамен RUSSCO, мастер-класс «Живая хирургия».
Организатор: Минздрав Нижегородской области, Ассоциация онкологов России, НИИКО «НОКОД», ПИМУ
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: MASCC Supportive Care Events
Организатор: College of American Pathologists (CAP) Events
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: SIOP Community Calendar
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: EBMT Educational Events & Meetings
Организатор: College of American Pathologists (CAP) Events
Организатор: European School of Oncology (ESO)